BRPI0414103A - compostos, produtos medicinal, e, método para a preparação de compostos - Google Patents

compostos, produtos medicinal, e, método para a preparação de compostos

Info

Publication number
BRPI0414103A
BRPI0414103A BRPI0414103-2A BRPI0414103A BRPI0414103A BR PI0414103 A BRPI0414103 A BR PI0414103A BR PI0414103 A BRPI0414103 A BR PI0414103A BR PI0414103 A BRPI0414103 A BR PI0414103A
Authority
BR
Brazil
Prior art keywords
compounds
preparation
treatment
medicinal products
addictions
Prior art date
Application number
BRPI0414103-2A
Other languages
English (en)
Inventor
Anja Fecher
Heinz Fretz
Kurt Hilpert
Volker Breu
Thomas Giller
Oliver Valdenaire
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0414103A publication Critical patent/BRPI0414103A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Abstract

"COMPOSTOS, PRODUTO MEDICINAL, E, MéTODO PARA A PREPARAçãO DE COMPOSTOS". Derivados de guanidina da fórmula geral (I), e hidratos ou solventes dos mesmos, como antagonistas de receptor de neuropeptídeo FF, para o tratamento de dor e hiperalgesia, de sintomas de retirada relativos à dependência de álcool, psicofarmacêuticos e nicotina, e para a prevenção ou eliminação destas dependências, para a regulação da liberação de insulina, da ingestão de alimentos, de funções da memória, da pressão sanguínea, do metabolismo de eletrólitos e energia, e para o tratamento de incontinência urinária.
BRPI0414103-2A 2003-09-05 2004-09-03 compostos, produtos medicinal, e, método para a preparação de compostos BRPI0414103A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH15262003 2003-09-05
PCT/CH2004/000556 WO2005023781A1 (de) 2003-09-05 2004-09-03 Guanidinderivate

Publications (1)

Publication Number Publication Date
BRPI0414103A true BRPI0414103A (pt) 2006-10-31

Family

ID=34230846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414103-2A BRPI0414103A (pt) 2003-09-05 2004-09-03 compostos, produtos medicinal, e, método para a preparação de compostos

Country Status (16)

Country Link
US (1) US7544691B2 (pt)
EP (1) EP1663993B1 (pt)
JP (1) JP2007504176A (pt)
KR (1) KR20060064065A (pt)
CN (1) CN1845907B (pt)
AT (1) ATE388943T1 (pt)
AU (1) AU2004270304A1 (pt)
BR (1) BRPI0414103A (pt)
CA (1) CA2536927A1 (pt)
DE (1) DE502004006515D1 (pt)
ES (1) ES2300807T3 (pt)
IL (1) IL173853A0 (pt)
NO (1) NO20061531L (pt)
PL (1) PL1663993T3 (pt)
RU (1) RU2006110738A (pt)
WO (1) WO2005023781A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DK1803444T3 (en) 2002-12-20 2019-02-25 Niconovum Ab PROCEDURE FOR PREPARING A NICOTIC PARTICULATE MATERIAL WITH A CRYSTALLINE CELLULOSE (ESPECIALLY MCC)
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
JP5766716B2 (ja) * 2009-12-24 2015-08-19 ノボマー， インコーポレイテッド 多環式グアニジン化合物の合成のための方法
WO2015002150A1 (ja) 2013-07-03 2015-01-08 株式会社新日本科学 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
EP3583090A4 (en) 2017-02-14 2020-12-30 Research Triangle Institute, International PROLINE-BASED NEUROPEPTIDE FF RECEIVER MODULATORS
CN108159031A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗苯丙胺类毒品成瘾药物中的应用和药物及制备方法
CN108159032A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505327A (en) 1967-08-07 1970-04-07 American Cyanamid Co Tetrahydroquinoxalinyl phosphates or thiophosphates
BE795257A (fr) 1972-02-10 1973-08-09 Thomae Gmbh Dr K Nouveaux oxazols
DE3334455A1 (de) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
WO2003026657A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Compounds for the treatment of pain
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
WO2003026667A1 (en) 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Quinazolino- and quinolino- guanidines as ligands for the neurop eptide ff (npff) receptors

Also Published As

Publication number Publication date
US20070123510A1 (en) 2007-05-31
RU2006110738A (ru) 2007-12-10
NO20061531L (no) 2006-04-04
ES2300807T3 (es) 2008-06-16
ATE388943T1 (de) 2008-03-15
CA2536927A1 (en) 2005-03-17
WO2005023781A1 (de) 2005-03-17
CN1845907B (zh) 2010-07-28
IL173853A0 (en) 2006-07-05
EP1663993A1 (de) 2006-06-07
JP2007504176A (ja) 2007-03-01
PL1663993T3 (pl) 2008-08-29
AU2004270304A1 (en) 2005-03-17
EP1663993B1 (de) 2008-03-12
US7544691B2 (en) 2009-06-09
DE502004006515D1 (en) 2008-04-24
CN1845907A (zh) 2006-10-11
KR20060064065A (ko) 2006-06-12

Similar Documents

Publication Publication Date Title
NO20061531L (no) Guanidinderivater
WO2008002245A8 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
NO20054743L (no) Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonister
WO2008002244A8 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
CA2945789C (en) Inhibiting the transient receptor potential a1 ion channel
WO2012054831A3 (en) Ready to use ketorolac formulations
NO20065878L (no) Terapeutiske forbindelser
EP4245299A3 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
BRPI0413849A (pt) metanossulfonato de etiléster de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2 -il-amino]-propiÈnico e seu uso como medicamento
NO20082445L (no) Neuropeptid-2 reseptor-agonister
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008150899A1 (en) Combination therapies for treatment of cancer and inflammatory diseases
WO2007081947A3 (en) Drug storage and dispensing devices and systems comprising the same
WO2012007159A3 (en) Novel gastro-retentive dosage forms
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2008006795A3 (en) Indole compounds
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
EA200870182A1 (ru) Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
NO20090125L (no) Benzimidazolderivater som skal anvendes som antagonist for CB1-reseptor
MXPA05012772A (es) Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.